Related Experiment Video
Updated: Sep 9, 2025
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Case Report: Polymyxin E-associated reversible leukopenia
Suxin Wan1, Jia-Quan Zhu2, Lihua Wang3
1Department of Pharmacy, Chongqing University Three Gorges Hospital, Chongqing University, Chongqing, China.
Introduction:
With the increasing challenge of antibiotic resistance, polymyxin E is considered a last-line treatment option for infections caused by highly resistant bacteria. However, its use may lead to various adverse reactions, such as nephrotoxicity, neurotoxicity, and allergic reactions.
Case Presentation:
This study describes a case of polymyxin E-associated leukopenia in a 50-year-old female treated for Klebsiella pneumoniae infection. During polymyxin E therapy, the patient developed leukopenia, with white blood cell (WBC) counts declining from 5.65×109/L to 0.91×109/L. The condition resolved progressively after the cessation of polymyxin E. The Naranjo scale yielded a score of 7 for polymyxin E-associated leukopenia, while other medications scored ≤0. The WHO-Uppsala Monitoring Centre (WHO-UMC) causality classification system categorized the relationship as 'probable.'
Conclusion:
These findings suggest that polymyxin E likely induces leukopenia, emphasizing the need for rigorous WBC monitoring during treatment and prompt discontinuation when hematologic abnormalities emerge to minimize patient health risks.
Insights
Polymyxin E, a last-resort antibiotic, may cause leukopenia (low white blood cell count). This case study highlights the importance of monitoring blood counts during treatment to ensure patient safety.
Area of Science:
- Infectious Diseases
- Pharmacology
- Hematology
Background:
- Polymyxin E is a critical antibiotic for multidrug-resistant bacterial infections.
- Adverse effects of polymyxin E include nephrotoxicity and neurotoxicity.
- Leukopenia is a potential, though less commonly reported, adverse effect.
Observation:
- A 50-year-old female patient developed leukopenia during treatment for Klebsiella pneumoniae infection.
- White blood cell counts decreased significantly from 5.65×10^9/L to 0.91×10^9/L.
- Leukopenia resolved after discontinuing polymyxin E therapy.
Findings:
- The Naranjo scale indicated a probable association between polymyxin E and leukopenia (score of 7).
- The WHO-UMC classification also supported a probable causal relationship.
- This case suggests polymyxin E can induce leukopenia.
Implications:
- Rigorous monitoring of white blood cell counts is crucial during polymyxin E treatment.
- Prompt cessation of polymyxin E is recommended upon detecting hematologic abnormalities.
- This vigilance can mitigate risks associated with polymyxin E-induced leukopenia.
Related Concept Videos
01:27Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
01:28Acute Pyelonephritis II: Diagnostic Studies and Management